StockData
Unicycive Therapeutics, Inc. logo

Unicycive Therapeutics, Inc. (UNCY) stock

UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$3.55−0.09 (-2.47%)

Close on Nov 13, 2026Market cap $98.89MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$98.89M
P/E ratio
–
Price to sales
–
Price to book
1.86
Dividend yield
–
Free cash flow yield
-28.16%

Fundamentals

Net income
-$36.21M
EPS, diluted
-$1.67
Free cash flow
-$29.35M
Book value per share
$1.86
Diluted shares
28M

Trading

Next earnings
Q3 FY2026, expected soon
Previous close
$3.64
Open
$3.63
Day's range
$3.52 – $3.69
Volume
690,182
Average volume (20 days)
1,058,869
Index membership
Russell 2000 (since Jun 2026)
Beta (5 years)
-0.80
52-week range
$3.33 – $8.74
RSI (14 days)
41.7
Volatility (1 year)
78.7%
Relative volume
0.76×
WACC
7.6%

On 1 of our idea list: More cash than they're worth

Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodUNCYS&P 500DifferenceUNCY per yearS&P 500 per year
1 month-4.8%-3.0%−1.8 pts
3 months-34.3%-2.8%−31.5 pts
Year to date-38.5%+11.5%−50.0 pts
1 year-33.4%+13.5%−46.9 pts
3 years-34.3%+77.7%−112.0 pts-13.1%+21.1%
5 years-86.9%+72.6%−159.5 pts-33.4%+11.5%

Seven years at a glance

Fiscal years 2019 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$34.64M

Net income

-$36.21M

EPS, diluted

–

Free cash flow

-$29.35M
Reported periodTrailing twelve months

Press releases

Releases Unicycive Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Unicycive Therapeutics

Pharmaceutical Preparations

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapies for kidney diseases and other medical conditions. The company's pipeline includes two primary therapeutic candidates: oxylanthanum carbonate, a nanoparticle lanthanum-based phosphate binder designed for treating hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate under development for acute kidney injury. Unicycive operates by licensing drug technologies from other pharmaceutical entities to advance them through clinical development, regulatory approval, and commercialization. Target populations include chronic kidney disease patients suffering from elevated phosphate levels and individuals with sudden kidney injury.

Company profile, executives and history

Unicycive Therapeutics stock: common questions

What is Unicycive Therapeutics's stock price?

UNCY closed at $3.55 on Nov 13, 2026, down 2.47% on the day. Over the past 52 weeks it traded between $3.33 and $8.74.

What is Unicycive Therapeutics's market cap?

Unicycive Therapeutics was worth $98.89M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.

What is UNCY's P/E ratio?

Unicycive Therapeutics lost money over fiscal 2025 (diluted EPS -$1.67), so it has no meaningful P/E ratio.

Does Unicycive Therapeutics pay a dividend?

No. Unicycive Therapeutics has not paid a cash dividend over the last twelve months.

When does Unicycive Therapeutics report earnings next?

Unicycive Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.

How has UNCY stock performed over the past year?

Including dividends, UNCY returned -33.4% over the past year, against +13.5% for the S&P 500.

How many UNCY shares are sold short?

5M shares were sold short at the latest FINRA report, 24.38% of the float, or 4.2 days of average trading volume.

Who are Unicycive Therapeutics's competitors?

Companies most similar to Unicycive Therapeutics by business, industry and size include AKBA, TVTX, XRTX, ARDX, RARE.

See a number that looks wrong?